BACKGROUND: Animal and cellular studies support the importance of autophagy inhibition in lymphangioleiomyomatosis (LAM). In a cohort of subjects with LAM, we tested the hypothesis that treatment with sirolimus and hydroxychloroquine (an autophagy inhibitor) at two different dose levels is safe and well tolerated. Secondary end points included changes in lung function. METHODS: This 48-week, two-center phase I trial evaluated the safety of escalating oral hydroxychloroquine doses (100-200 mg) given twice a day in combination with sirolimus to eligible patients ≥ 18 years old with LAM. Subjects received combination therapy for 24 weeks followed by an observation phase without taking study drugs for an additional 24 weeks. RESULTS: Fourteen patients provided written informed consent. Thirteen were treated in cohorts of three patients each with escalating hydroxychloroquine doses (200 and 400 mg) and an extension phase at the 400-mg dose. The most common adverse events were mucositis, headache, and diarrhea. No drug-related serious adverse events were reported. Secondary end points showed improvement in lung function at 24 weeks, with a decrease in lung function at the 48-week time point. When the higher dose of hydroxychloroquine was analyzed separately, FEV1 and FVC remained stable at 48 weeks, but the 6-min walk distance showed a decrease toward baseline. CONCLUSIONS: The combination of sirolimus and hydroxychloroquine is well tolerated, with no dose-limiting adverse events observed at 200 mg twice a day. Potential effects on lung function should be explored in larger trials. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01687179; URL: www.clinicaltrials.gov.
BACKGROUND: Animal and cellular studies support the importance of autophagy inhibition in lymphangioleiomyomatosis (LAM). In a cohort of subjects with LAM, we tested the hypothesis that treatment with sirolimus and hydroxychloroquine (an autophagy inhibitor) at two different dose levels is safe and well tolerated. Secondary end points included changes in lung function. METHODS: This 48-week, two-center phase I trial evaluated the safety of escalating oral hydroxychloroquine doses (100-200 mg) given twice a day in combination with sirolimus to eligible patients ≥ 18 years old with LAM. Subjects received combination therapy for 24 weeks followed by an observation phase without taking study drugs for an additional 24 weeks. RESULTS: Fourteen patients provided written informed consent. Thirteen were treated in cohorts of three patients each with escalating hydroxychloroquine doses (200 and 400 mg) and an extension phase at the 400-mg dose. The most common adverse events were mucositis, headache, and diarrhea. No drug-related serious adverse events were reported. Secondary end points showed improvement in lung function at 24 weeks, with a decrease in lung function at the 48-week time point. When the higher dose of hydroxychloroquine was analyzed separately, FEV1 and FVC remained stable at 48 weeks, but the 6-min walk distance showed a decrease toward baseline. CONCLUSIONS: The combination of sirolimus and hydroxychloroquine is well tolerated, with no dose-limiting adverse events observed at 200 mg twice a day. Potential effects on lung function should be explored in larger trials. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01687179; URL: www.clinicaltrials.gov.
Authors: Brian A Boone; Nathan Bahary; Amer H Zureikat; A James Moser; Daniel P Normolle; Wen-Chi Wu; Aatur D Singhi; Phillip Bao; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Herbert J Zeh Journal: Ann Surg Oncol Date: 2015-04-24 Impact factor: 5.344
Authors: Andrey Parkhitko; Faina Myachina; Tasha A Morrison; Khadijah M Hindi; Neil Auricchio; Magdalena Karbowniczek; J Julia Wu; Toren Finkel; David J Kwiatkowski; Jane J Yu; Elizabeth Petri Henske Journal: Proc Natl Acad Sci U S A Date: 2011-07-11 Impact factor: 11.205
Authors: D N Franz; A Brody; C Meyer; J Leonard; G Chuck; S Dabora; G Sethuraman; T V Colby; D J Kwiatkowski; F X McCormack Journal: Am J Respir Crit Care Med Date: 2001-08-15 Impact factor: 21.405
Authors: K Matsui; A Tatsuguchi; J Valencia; Z x Yu; J Bechtle; M B Beasley; N Avila; W D Travis; J Moss; V J Ferrans Journal: Hum Pathol Date: 2000-10 Impact factor: 3.466
Authors: Devalingam Mahalingam; Monica Mita; John Sarantopoulos; Leslie Wood; Ravi K Amaravadi; Lisa E Davis; Alain C Mita; Tyler J Curiel; Claudia M Espitia; Steffan T Nawrocki; Francis J Giles; Jennifer S Carew Journal: Autophagy Date: 2014-05-20 Impact factor: 16.016
Authors: Rebecca A Barnard; Luke A Wittenburg; Ravi K Amaravadi; Daniel L Gustafson; Andrew Thorburn; Douglas H Thamm Journal: Autophagy Date: 2014-05-20 Impact factor: 16.016
Authors: Myrna R Rosenfeld; Xiaobu Ye; Jeffrey G Supko; Serena Desideri; Stuart A Grossman; Steven Brem; Tom Mikkelson; Daniel Wang; Yunyoung C Chang; Janice Hu; Quentin McAfee; Joy Fisher; Andrea B Troxel; Shengfu Piao; Daniel F Heitjan; Kay-See Tan; Laura Pontiggia; Peter J O'Dwyer; Lisa E Davis; Ravi K Amaravadi Journal: Autophagy Date: 2014-05-20 Impact factor: 16.016
Authors: Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Yan Tang; Souheil El-Chemaly; Angelo Taveira-Dasilva; Hilary J Goldberg; Shefali Bagwe; Ivan O Rosas; Joel Moss; Carmen Priolo; Elizabeth P Henske Journal: Chest Date: 2019-07-09 Impact factor: 9.410
Authors: Zhi-Wei Lai; Ryan Kelly; Thomas Winans; Ivan Marchena; Ashwini Shadakshari; Julie Yu; Maha Dawood; Ricardo Garcia; Hajra Tily; Lisa Francis; Stephen V Faraone; Paul E Phillips; Andras Perl Journal: Lancet Date: 2018-03-15 Impact factor: 79.321
Authors: Anthony M Lamattina; Angelo Taveira-Dasilva; Hilary J Goldberg; Shefali Bagwe; Ye Cui; Ivan O Rosas; Joel Moss; Elizabeth P Henske; Souheil El-Chemaly Journal: Chest Date: 2018-08-23 Impact factor: 9.410